It is estimated that more than 339 million people had Asthma globally in 2016
According to WHO estimates, there were 417,918 deaths due to asthma at the global level in 2016
Approx. 40% of people with asthma may use non-orthodox remedies with non-disclosure to practitioners being common
TAKL has demonstrated benefits in symptomatic asthma and COPD patients uncontrolled on standard care medication.
Used as adjunctive support, TAKL has demonstrated:
Has been shown to: